PSO’s CONFERENCE

PRESENTATION BY

ROHIT SHARMA

KOTA

31/01/2024
 KEY ACHIEVMENTS OF 2023 -24

1. Visited Doctors Regularly

2. Visited Chemists Regularly

3. Maximum POB done

4. Conducted DAW & NPDC Camp

5. Regular RCPA & Reminder to doctors

 2023 - 24 PERFORMANCE

ACTUAL TARGET ACTUAL

% To Cum. Gr. %
PERIOD 2022-23 2023-24 2023-24
Target
(Rs. LAKH) (Rs. LAKH) (Rs. LAKH)

.79 7.50 10.04 134 1026

1st QTR.

7.35 8.16 9.73 119 170

2nd QTR.

7.69 7.41 6.37 86 91

3rdQTR.

6.73 6.93 7.68 111 58

4th QTR

22.56 30.00 33.82 113 336

TOTAL YEAR
WORK PERFORMANCE REVIEW - JAN & FEB 2024

NO. OF SEs
PARAMETER
JAN FEB
A. Doctor Coverage
> 96%
92 - 96%
< 92%

B. Doctor Call Avg.

14 & more
12 - 13
11 & less

C. Last week sales

35% or less
36% - 44%
45% & above
 MAJOR BRAND PERFORMANCE
2023 – 24

Quarterly YPM (Rs._L)

Cum. Gth
Brand / Group
%
I II III IV

ANTI-DIABETIC .11 .12 .09 .09

MEFTAL GROUP 7.71 5.82 3.48 4.36

TUSQ GROUP .89 2.36 1.76 2.25

BLUMOX/CA GROUP .05 0 0 .01

EXTACEF O/I .18 .18 .04 .06

DICLOTAL GROUP .91 .93 .60 .77

OTHERS .40 .49 .49 .32

TOTAL 10.25 9.90 6.46 7.86

 TERRITORY SALES COMMITMENT
2024 -2025

2023-24 2024-25 Commitment

2024-25 Cum.
Actual Commitment as % To
Target Rs. L Gr. %
Rs. L Rs. L Target

APR 3.45 3.36 3.50 104 1

MAY 3.24 3.20 3.40 106 5

JUN 3.35 3.20 3.40 106 2

I QTR 10.04 9.76 10.30 106 3

II QTR 9.73 10.63 11.00 103 13

III QTR 6.37 9.65 10.00 104 57

IV QTR 7.68 9.04 9.50 105 24

YEAR 33.82 39.08 40.80 104 21

 MAJOR BRAND SALES COMMITMENT
April - June 2024

Ist Qtr Sales Rs. L

Cum. Gth.
%
Brand / Group
Apr May Jun

2023 2024 2023 2024 2023 2024

ANTI-DIABETIC .04 .20 .06 .20 .02 .20 400

MEFTAL GROUP 2.24 2.50 2.63 2.70 2.83 2.90 5

TUSQ GROUP .58 .60 .17 .60 .14 .60 114

BLUMOX/CA
.02 .20 .04 .20 0 .20 900
GROUP
EXTACEF O/I .11 .15 .07 .10 .01 .10 84
DICLOTAL
.32 .40 .17 .40 .42 .50 43
GROUP
OTHERS .15 .20 .10 .20 .15 .20 50

TOTAL 3.46 4.25 3.24 4.40 3.57 4.70 30